Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effect of Hand Massage Stimulation on Pain and Menstrual Symptoms in Primary Dysmenorrhea

24. oktober 2026 oppdatert av: Melike TAN ÇELİK, Inonu University

Effekt av håndmassasjestimulering på smerte og menstruasjonssymptomer ved primær dysmenoré

Purpose of this study: The purpose of this study is to determine the effect of hand massage stimulation techniques on pain, daily menstrual symptoms and nausea and vomiting in primary dysmenorrhea.

H1a: Hand massage stimulation techniques reduce pain in primary dysmenorrhea. H1b: Hand massage stimulation techniques reduce daily menstrual symptoms in primary dysmenorrhea.

The data were collected from students suffering from primary dysmenorrhea pain studying at İnönü University Faculty of Health Sciences. Seed therapy (su-jok) will be applied by researcher Melike TAN ÇELİK who has a basic level su-jok therapy certificate.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The aim of this study is to determine the effect of hand massage stimulation techniques on pain, daily menstrual symptoms and nausea and vomiting in primary dysmenorrhea.

Data will be collected from students experiencing Primary Dysmenorrhea at İnönü University Faculty of Health Sciences. Participants who meet the inclusion criteria and agree to participate will be informed about the study, and participants who fill out the "Minimum Informed Consent Form" will be included in the study. Data collection forms will be applied by the researcher, paying attention to student privacy, and the pre-test data collection phase will be completed. After the pre-test data collection phase is completed, hand stimulation techniques (su-jok seed therapy) will be applied by the researcher to the students experiencing primary dysmenorrhea in the experimental group. Students experiencing primary dysmenorrhea will be given detailed information about the application in the laboratory at the faculty, and pain points will be determined according to the reflections of the organs on the hand. Black pepper seeds, one of the seeds used in the treatment of primary dysmenorrhea, will be placed on the detected points and removed after 5-6 hours. This application will be done a total of 3 times in each cycle, on the 1st, 2nd and 3rd day of the menstrual cycle. A total of 2 cycles of application will be made, the first menstrual cycle being the 1st cycle, and the final test data will be collected 5-6 hours after each application. This intervention will be carried out by Melike Tan, and the researcher has a basic level Su Jok therapy certificate. No intervention will be applied to the students experiencing primary dysmenorrhea in the control group, but the Personal Information Form, Visual Analog Scale (VAS), and Daily Menstrual Symptom Assessment Scale (GMDSS) will be administered simultaneously to the experimental group.

Studietype

Intervensjonell

Registrering (Faktiske)

60

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Malatya, Tyrkia (Türkiye)
        • İnönü University Faculty of Health Sciences

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 50 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Participant who is 18 years or older
  • Participant diagnosed with primary dysmenorrhea by a gynecologist
  • Participant who has had regular menstruation in the last 6 months
  • Participant whose menstrual pain continues for 8-72 hours

Exclusion Criteria:

  • Participant who is pregnant
  • Participant who has given birth before or has a history of pregnancy
  • Participant using intrauterine or oral contraceptives
  • Participant who is taking any anti-inflammatory, analgesic and psychotherapeutic medication
  • Participant with any history of pelvic pathology or pelvic surgery
  • Participant with any neurological or systemic disease

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: seed therapy ( su-jok)

Group that received seed therapy ( su- jok )

In hand massage, tiny swellings called "ball conformity" occur on the reflection points of the organs where the complaint occurs on the hands and feet. It is argued that the sensitivity of the relevant point to pressure has a direct correlation with the level of pain in the body part. A rod called a "diagnostic probe" or "diagnostic rod" made of metal, plastic or wood, approximately ten centimeters long, is used to detect the painful point on the hand and foot. After the correct point is detected, various techniques are applied to stimulate these points and ensure the continuation of the energy flow.In this study, the seed massage technique, which does not cause any side effects among the hand massage stimulation methods, requires a basic level certificate for its use, does not require being a health professional, and can be easily applied by anyone, will be used. Seed massage is a method applied by first detecting pain through a probe on the points of the organs reflected on the hand

Ingen inngripen: standard maintenance

group not receiving seed therapy ( su- jok)

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Visual Analog Scale (VAS)
Tidsramme: At baseline (pre-intervention) and immediately after completion of seed therapy]

Description: VAS is a scale created in the range of 0-10 cm. According to the scale, 0 cm means the pain is not severe at all, and 10 cm means unbearable pain. On the scale, 0-44 mm indicates mild pain, 45-74 mm indicates moderate pain, and 75-100 mm indicates severe pain.

Time Frame: At baseline (pre-intervention) and immediately after completion of seed therapy.

At baseline (pre-intervention) and immediately after completion of seed therapy]

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Daily Menstrual Symptom Assessment Scale (DMSA)
Tidsramme: At baseline (pre-intervention) and immediately after completion of seed therapy]

The GMMSS was developed by Taylor in 1979 to assess symptoms and their severity during menstruation. The Turkish validity and reliability of the scale were established by Oskay et al. in 2008. The scale consists of seventeen items, with each symptom severity scored between 0 and 5, and there are no subscales. An increase in the score indicates an increase in symptom severity. In Oskay et al.'s study, the Cronbach's alpha value of the scale was found to be 0.88.

[Time Frame: Initially (before intervention) and immediately after completion of insemination treatment]

At baseline (pre-intervention) and immediately after completion of seed therapy]

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Esra GÜNEY, PhD, Inonu University

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. september 2025

Primær fullføring (Faktiske)

1. mai 2026

Studiet fullført (Faktiske)

1. september 2026

Datoer for studieregistrering

Først innsendt

13. april 2026

Først innsendt som oppfylte QC-kriteriene

18. april 2026

Først lagt ut (Faktiske)

22. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

27. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Research results will be shared

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere